 | ||
|
Company Overview
Braasch Biotech LLC is a privately held, preclinical-stage Vaccine Company that specializes in
the discovery, early stage development and commercialization of an exciting new class of
biopharmaceutical vaccine products for the human and animal healthcare market.
After several years of successful foundational science, development
and intellectual property generation, the company is now ready to advance to a critical
monetization stage of its lifecycle. We have recently completed key proof-of-concept testing
and intellectual property activities and are now actively developing a diversified pipeline
of second-generation somatostatin-based immunopharmaceutical vaccines for humans and animals.
Braasch's platform technology has significant opportunities to create
a large pipeline of new products. Delivering new treatments, categories and segments for
innovative Growth Hormone ("GH") and Insulin-like Growth Factor -1 ("IGF-1") treatment
alternatives which address some of the highest valued markets available in medicine.
Copyright © 2010 Braasch Biotech LLC. All rights
reserved.
|
News and Releases
|